Kymera Investor Day Presentation Deck

KT-333 Demonstrates Highly Selective Degradation of STAT3 KYMERA Deep mass spectrometry-based proteomics to assess STAT3 selectivity performed In hPBMC and SU-DHL-1 cancer line (shown), treatment with KT-333 degrader led to selective degradation of only STAT3 protein ©2021 KYMERA THERAPEUTICS, INC. -Log10(p-Value) 8 t 2 0 Change in Protein Levels 10x DC95 at 8h in SU-DHL-1 STAT3 O KYMERA R&D DAY - December 16th, 2021 STAT6 STAT4 STAT5A STAT2 STAT5B STAT1 T -2.5 2.5 Log2(300nM KT-333/DMSO) 0.0 PAGE 61

View entire presentation